Alle afleveringen
427 afleveringen, van nieuw naar oud
-
Sep 01 2023 This Week in Cardiology
1 september 2023 · 31 min
ESC Wrap-up 1: Obesity, heart failure with preserved EF and reduced EF, AF, frailty, evidence translation, and catheter ablation are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. FRAIL AF
-FRAIL-AF Study
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066485
-The Most Important Study From ESC: FRAIL-AF
https://www.medscape.com/viewarticle/996063
II. STEP-HFpEF
Wegovy Scores HFpEF Benefits in People With Obesity
https://www.medscape.com/viewarticle/995844
GLP-1 Agonist Semaglutide in HFpEF Cleared Low Bar
https://www.medscape.com/viewarticle/995872
Semaglutide's Big Step in HFpEF With Obesity: Investigator Inteview
https://www.medscape.com/viewarticle/995673
-Semaglutide in Obese Patients With HFpEF
https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
III. NOAH AFNET 6
Anticoagulation No Benefit in Presumed AF Detected by Cardiac Devices
https://www.medscape.com/viewarticle/995861
How Much AF Warrants Anticoagulation? NOAH-AFNET 6 Provides Clues
https://www.medscape.com/viewarticle/995871
-NOAH AFNET-6 – NEJM
https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
IV. ADVENT
Pulsed Field Ablation Challenges Conventional Devices in AF
https://www.medscape.com/viewarticle/995884
Pulsed Field Ablation Noninferior but Underwhelming in ADVENT
https://www.medscape.com/viewarticle/995898
-PPFA vs Thermal Ablation for PAF
https://www.nejm.org/doi/10.1056/NEJMoa2307291
V. BUDAPEST CRT
Impact of RV Pacing in Heart Failure, CRT Benefit Shown in BUDAPEST-CRT
https://www.medscape.com/viewarticle/996035
Supporting Evidence for a Common Practice: BUDAPEST CRT
https://www.medscape.com/viewarticle/995880
-BUDAPEST CRT Study: European Heart Journal
https://doi.org/10.1093/eurheartj/ehad591
VI. CASTLE HTx
Advanced HF No Obstacle to AF Ablation Success: CASTLE-HTx
https://www.meds…
-
Aug 25 2023 This Week in Cardiology
25 augustus 2023 · 30 min
GLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Obesity and HFpEF
GLP-1 Agonists in HFpEF With Obesity: Are We There Yet? https://www.medscape.com/viewarticle/993980
Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844
- Semaglutide in Obese Patients With HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
- Rationale/Protocol Paper https://doi.org/10.1016/j.jchf.2023.05.010
II. DOAC for Subclinical AF
- NOAH-AFNET 6 Rationale/Protocol https://doi.org/10.1016/j.ahj.2017.04.015
- NOAH-AFNET 6 Trial Results https://www.nejm.org/search?q=NOAH+AFNET
III. Renal Denervation
ReCor Renal Denervation System Safe, Effective: FDA Panel https://www.medscape.com/viewarticle/995741
FDA Panel Split on Efficacy of Spyral Renal Denervation https://www.medscape.com/viewarticle/995800
SPYRAL HTN-ON MED https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00455-X/fulltext
IV. Maintenance of Certification
As MOC Debate Heats Up, Cardiology Societies Weigh In https://www.medscape.com/viewarticle/moc-debate-heated-cardiology-societies-weigh-2023a1000jju
Features
Mandrola's 5 Things to Look for at the Upcoming ESC 2023
https://www.medscape.com/viewarticle/995614
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information …
-
Aug 18 2023 This Week in Cardiology
18 augustus 2023 · 30 min
ICD generator change, less is more in VT management, co-morbidity in HF, and SGLT2i after AF ablation are the topics discussed by John Mandrola, MD, in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ICD Gen Change
- Patients' Perspectives Regarding Generator Exchanges of Implantable Cardioverter Defibrillators https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.122.009827
- DEFINITE https://www.nejm.org/doi/10.1056/nejmoa033088
- SCD-HeFT https://www.nejm.org/doi/full/10.1056/nejmoa043399
- DANISH https://www.nejm.org/doi/10.1056/NEJMoa1608029
- Poole and colleagues; 11-year follow-up of SCD-HeFT https://doi.org/10.1016/j.jacc.2020.05.061
- Editorial – Howell/Stecker https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010266
II. VT Therapy
Crossed Wires: Ischemia Testing and Monomorphic VT Storm
https://www.medscape.com/viewarticle/995401
- Cleveland Clinic Study
https://doi.org/10.1016/j.jacep.2023.04.030
III. Co-Morbidity in HF
- Hospital admissions in the last year of life of patients with heart failure
https://doi.org/10.1093/ehjqcco/qcad047
- Four Horsemen of Apocalypse Lecture
http://www.louisvillelectures.org/imblog/2017/10/5/whw8sf0m1k0wi6lm6kvjsx4nxzzjg5
IV. SGLT2i After Ablation for AF
SGLT2 Inhibitors Curb AF Post-Ablation Recurrences in Diabetes
https://www.medscape.com/viewarticle/995415
- Observational Study – Abu-Qaoud et al
https://www.jacc.org/doi/full/10.1016/j.jacep.2023.06.008
- Meta-analysis SGLT2i and AF
https://www.ahajournals.org/doi/full/10.1161/JAHA.121.022222
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrin…
-
Aug 11, 2023 This Week in Cardiology Podcast
11 augustus 2023 · 29 min
Observational studies, another defense of digoxin, CTO-PCI, BP measurement, and a possible revolution in cardiovascular protection are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Observational Research
Yeh; Credibility in Observational Research https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064645
Hernan; Causal Language in Observational Research https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2018.304337
Wang; RCT Duplicate Initiative https://jamanetwork.com/journals/jama/fullarticle/2804067
II. Defense of Digoxin
Brophy; Beta Blockers, Digoxin, or Both https://doi.org/10.1016/j.cjca.2023.06.009
Dorian editorial https://doi.org/10.1016/j.cjca.2023.07.013
Ziff Digoxin Meta-analysis https://www.bmj.com/content/351/bmj.h4451.long
DIG trial https://www.nejm.org/doi/full/10.1056/nejm199702203360801
Davila Analysis of DIG Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801940/
Kotecha Meta-analysis of Beta Blockers https://pubmed.ncbi.nlm.nih.gov/25193873/
RATE-AF https://jamanetwork.com/journals/jama/fullarticle/2774407
III. CTO-PCI
PCI of Chronic Total Occlusions Improves Angina, Quality of Life in Trials https://www.medscape.com/viewarticle/994739
JAMA Network Open Meta-analysis
IV. BP Measurement
One Size Doesn't Fit All in Blood Pressure Measurement https://www.medscape.com/viewarticle/995216
Ishigami Blood Pressure Measurement Comparison
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2807853
V. GLP-1 SELECT Trial
Semaglutide Cuts Cardiovascular Events in Landmark Trial
https://www.medscape.com/viewarticle/995270
SELECT Protocol Paper
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
T…
-
Aug 04 2023 This Week in Cardiology
4 augustus 2023 · 25 min
Listener feedback re observational studies, surgeons' dissent from recent guidelines, aspirin for primary prevention, and fish oil are the topics discussed by John Mandrola.MD in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Heart Surgeons Dissent
Surgical Groups Push Back Against New Revascularization Guidelines
https://www.medscape.com/viewarticle/966153
New Revascularization Guidelines: Key Points and Navigating Controversies
https://www.medscape.com/viewarticle/972014
- AHA Guidelines - https://doi.org/10.1161/CIR.0000000000001168
- AATS statement 2023 https://doi.org/10.1016/j.jtcvs.2023.03.001
- Yusef and colleagues 1994 Meta-analysis - https://doi.org/10.1016/S0140-6736(94)91963-1
- 10-year SYNTAXES https://doi.org/10.1016/S0140-6736(19)31997-X
- Surgeons' argument 2021 https://doi.org/10.1016/j.athoracsur.2021.12.003
- FAME 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
- Gaudino Meta-analysis of Medical Therapy vs CABG https://doi.org/10.1016/j.jtcvs.2022.06.003
- NOBLE https://doi.org/10.1016/S0140-6736(19)32972-1
- EXCEL 5 years https://www.nejm.org/doi/full/10.1056/nejmoa1909406
II. ASA for Primary Prevention
Daily Aspirin Challenged in Primary Stroke Prevention: ASPREE
https://www.medscape.com/viewarticle/994963
- ASPREE – All-cause mortality
- ASPREE (MACE and Bleeding) https://www.nejm.org/doi/full/10.1056/NEJMoa1805819
- ASPREE (disability) https://www.nejm.org/doi/full/10.1056/NEJMoa1800722
- JAMA Network Open Subanalysis https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807630
III. Fish Oil
- OMEMI Substudy https://doi.org/10.1016/j.clnu.2023.07.002
- Gencer and colleagues Meta-analysis - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654
- OMEMI Main Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.052209
You may also like:
Medscape editor-in-chief Er…
-
Jul 28 2023 This Week in Cardiology
28 juli 2023 · 28 min
Antiarrhythmic drugs in patients with CAD, observational studies, GLP-1 agonists, and the subcutaneous ICD are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. AAD in Patients with CAD
- The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease
https://doi.org/10.1016/j.jacep.2022.12.021
- Three Questions for Evidence-Based Cardiac Electrophysiology
https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381
- The Cardiac Arrhythmia Suppression Trial (CAST) https://www.nejm.org/doi/full/10.1056/nejm198908103210608
II. GLP-1 Agonists
Tirzepatide Powers Weight Loss in Two More Pivotal Trials https://www.medscape.com/viewarticle/994889
Semaglutide Use Surges in US Adults With Type 2 Diabetes https://www.medscape.com/viewarticle/994873
- Tirzepatide Once Weekly for the Treatment of Obesity
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
https://doi.org/10.1016/S0140-6736(23)01200-X
III. S-ICD
S-ICD Shows Virtues, Limits in 'Real World' Postmarket Study https://www.medscape.com/viewarticle/994851
- Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System https://doi.org/10.1016/j.jacc.2023.05.034
- Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
- Letter to the Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert …
-
Jul 21 2023 This Week in Cardiology
21 juli 2023 · 26 min
Listener feedback, conduction system pacing, eating fish vs fish pills, exercise, and an RCT for diet are the topics discussed by John Mandrola,.MD, in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback Monitor HF and AHA
Jun 02, 2023 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/992678
- Link to the ACC Email -- https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/07/18/17/21/monitor-hf
- Tweet From Anthony Pearson
https://twitter.com/skepcard/status/1681288604990189574
II. Conduction System Pacing
- Clinical Outcomes in Conduction System Pacing Compared to Right Ventricular Pacing in Bradycardia https://doi.org/10.1016/j.jacep.2022.10.016
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women https://www.acpjournals.org/doi/abs/10.7326/0003-4819-117-12-1016
III. Fish Oil
Omega-3s and AF: No Added Risk From Eating Fish but High-Dose Supplement Questions Persist https://www.medscape.com/viewarticle/994559
- Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation
https://www.jacc.org/doi/full/10.1016/j.jacc.2023.05.024
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://www.nejm.org/doi/full/10.1056/nejmoa1812792
- Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654
IV. Exercise
Even Exercise by 'Weekend Warriors' Can Cut CV Risk
https://www.medscape.com/viewarticle/994617
- Accelerometer-Derived "Weekend Warrior" Physical Activity and Incident Cardiovascular Disease https://jamanetwork.com/journals/jama/article-abstract/2807286
V. Diet
Cognitive Benefit of Highly Touted MIND Diet Questioned
https://www.medscape.com…
-
July 14 2023 This Week in Cardiology
14 juli 2023 · 28 min
Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Carotid Stenting CMS Proposal
Expanded Coverage of Carotid Stenting in CMS Draft Proposal
https://www.medscape.com/viewarticle/994315
No Added Benefit From Revascularization in Low-Risk CAS
https://www.medscape.com/viewarticle/992524
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311
- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy
https://doi.org/10.1016/S0140-6736(21)01910-3
- SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017
- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730
II. Paclitaxel
FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253
- FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions
III. Inclisiran
FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185
- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
https://doi.org/10.1093/eurheartj/ehac615
- Inclisiran and cardiovascular events: a patient-level analysis of phase III tr…
-
Jul 7 2023 This Week in Cardiology
7 juli 2023 · 28 min
European HTN Guidelines, vitamin D, bempedoic acid, and leadless pacing, with some critical appraisal techniques thrown in, are the topics John Mandrola, MD, tackles in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. European Hypertension Guidelines
New ESH Hypertension Guidelines Aim for Simplified Message
https://www.medscape.com/viewarticle/993913
- 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)
https://pubmed.ncbi.nlm.nih.gov/37345492/
II. Vitamin D
CV Benefit From Vitamin-D Caps Hinted in Huge D-Health Trial
https://www.medscape.com/viewarticle/993996
- Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial
https://www.bmj.com/content/381/bmj-2023-075230
- Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials
https://jamanetwork.com/journals/jamacardiology/fullarticle/2735646
III. Bempedoic Acid
'Striking' Benefit of Lipid Lowering in Primary Prevention
https://www.medscape.com/viewarticle/993666
- Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
https://jamanetwork.com/journals/jama/fullarticle/2806646
- Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Disease
https://jamanetwork.com/journals/jama/fullarticle/2806647
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
https://www.nejm.org/doi/full/10.1056/NEJMoa2215024
IV. Leadless Pacing
FDA Approves First Leadless Dual-Chamber Pacing System
https://www.medscape.com/viewarticle/994033
- A Dual-Chamber Leadless Pacemaker
https://www.nejm.org/doi/full/10.1056/NEJ…
-
Jun 23 2023 This Week in Cardiology
23 juni 2023 · 32 min
Starting HF meds during hospitalization for HF, Impella, testosterone, and colchicine are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Starting HF Meds During Hospitalization for HF
Starting Indicated Heart Failure Meds In-Hospital: Progress, Opportunities https://www.medscape.com/viewarticle/993539
- Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction https://www.jacc.org/doi/full/10.1016/j.jchf.2023.04.015
II. Impella
- Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock
https://jamanetwork.com/journals/jamacardiology/fullarticle/2806562
- Evidence Generation for Novel Cardiovascular Devices—Putting the Horse Back in Front of the Cart
https://jamanetwork.com/journals/jamacardiology/fullarticle/2806565
III. Testosterone
Big Trial Reassures on Heart Safety of Testosterone in Men
https://www.medscape.com/viewarticle/993322
- Cardiovascular Safety of Testosterone-Replacement Therapy
https://www.nejm.org/doi/full/10.1056/NEJMoa2215025
IV. Colchicine for CV Disease
Low-Dose Colchicine Approved for CVD: Now What?
https://www.medscape.com/viewarticle/993578
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/nejmoa1912388
- Colchicine in Patients with Chronic Coronary Disease
https://www.nejm.org/doi/full/10.1056/nejmoa2021372
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.med…
-
June 16 This Week in Cardiology
16 juni 2023 · 28 min
AF screening, BNP, a new SGLT2 inhibitor, a sky-is-blue study, and the UK Mini Mitral surgical trial are discussed in this week's podcast Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I AF Screening
- Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064361
- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01698-6
- Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders https://www.jacc.org/doi/full/10.1016/j.jacc.2019.09.050
- Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362
- Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design https://doi.org/10.1093/europace/euw319
- Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068511/
II Frailty and GDMT of HFrEF
Frailty Linked to Lower Use of Guideline Treatments in HFrEF
https://www.medscape.com/viewarticle/993218
- Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction https://www.ahajournals.org/doi/10.1161/JAHA.122.026844
III Sotagliflozin
FDA Approves New Drug, Sotagliflozin, for Heart Failure
https://www.medscape.com/viewarticle/992518
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa2030186
- Sotagliflozin in Patients with Diabetes and Recent Wor…
-
June 9 This Week in Cardiology
9 juni 2023 · 29 min
Impella, digital health, low-value processes, are tricuspid valve interventions with pacing leads are the topics Dr. John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Impella Class I Recall
FDA Class I Recall for Some Abiomed Impella Heart Pumps
https://www.medscape.com/viewarticle/992845
- A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention
https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.112.098194
- Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction
https://doi.org/10.1016/j.jacc.2016.10.022
https://www.sciencedirect.com/science/article/pii/S0735109716367675?via%3Dihub
- The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support
https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.044007
- Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
https://jamanetwork.com/journals/jama/fullarticle/2761003
- Danish Cardiogenic Shock Trial (DanShock)
https://clinicaltrials.gov/ct2/show/NCT01633502
II. Wearable Devices
- Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805753 doi:10.1001/jamanetworkopen.2023.16634
- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial
https://doi.org/10.1016/S0140-6736(21)01698-6
h…
-
June 2 This Week in Cardiology
2 juni 2023 · 28 min
Listener feedback on the most important study in a decade, MONITOR-HF, a flawed paper and analysis, and the tension between pathos and logos are the topics John Mandrola, MD discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
Earlier Anticoagulation Safe in Stroke With AF: ELAN
https://www.medscape.com/viewarticle/992411
- Early versus Later Anticoagulation for Stroke with Atrial Fibrillation
https://www.nejm.org/doi/full/10.1056/NEJMoa2303048
- Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/nejmoa1301092
II. Monitor HF
CardioMEMS Boosts QoL, Curbs HF Hospitalizations: MONITOR-HF
https://www.medscape.com/viewarticle/992333
- Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial
https://doi.org/10.1016/S0140-6736(23)00923-6
- Remote pulmonary artery pressure monitoring in heart failure care: part of the new normal?
https://doi.org/10.1016/S0140-6736(23)01010-3
- Sowell's A Conflict of Visions
https://en.wikipedia.org/wiki/A_Conflict_of_Visions
III. Intensive BP Treatment in Older Patients – Pathos vs Logos
- Clinical Outcomes of Intensive Inpatient Blood Pressure Management in Hospitalized Older
Adultshttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805021
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our…
-
May 26 2023 This Week in Cardiology
26 mei 2023 · 32 min
An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. HRS Meeting Recap
II. Impella in VT ablation
- First-in-human Experience with Impella 5.0/5.5 for High-Risk Patients with Advanced Heart Failure Undergoing VT Ablationhttps://www.jacc.org/doi/10.1016/j.jacc.2023.05.012
III. Sacubitril/Valsartan
ARNI Bests ARB to Reduce NT-proBNP in Stabilized Preserved-EF HF
https://www.medscape.com/viewarticle/992461
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
https://www.jacc.org/doi/10.1016/j.jacc.2023.04.019
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
https://www.nejm.org/doi/full/10.1056/nejmoa1908655
- Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
https://doi.org/10.1093/eurheartj/ehad344
- Bogdan Tweet
https://twitter.com/bogdienache/status/1660356776204595201?s=20
IV. Big Change in Reporting of Medical Evidence – Elan Trial
- Early versus Later Anticoagulation for Stroke with Atrial Fibrillationhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303048
- Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial https://doi.org/10.1177/23969873221106043
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob H…
-
May 19 2023 This Week in Cardiology
19 mei 2023 · 29 min
When to use an ICD, risk stratification for HCM, blending EP and structural cardiology to improve care in post-TAVI patients, and hsTroponins are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ICD in Patients with NICM
Simple Risk Score Predicts VT in Nonischemic Cardiomyopathy
https://www.medscape.com/viewarticle/992018
- Declining Risk of Sudden Death in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
- Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
- Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar https://doi.org/10.1093/eurheartj/ehy437
- RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure (BRITISH) https://clinicaltrials.gov/ct2/show/NCT05568069
II. Risk Stratification in HCM
- Changing Risk Stratification in Hypertrophic Cardiomyopathy? https://www.medscape.com/viewarticle/992014
- NOAH–AFNET 6 trial terminates ahead of time (NOAH AFNET 6 trial) https://dzhk.de/en/news/latest-news/article/noah-afnet-6-trial-terminates-ahead-of-time-noah-afnet-6-trial/
III. Blending EP and Structural to Improve TAVI Care
- Impact of Right Ventricular Pacing in Patients With TAVR Undergoing Permanent Pacemaker Implantation https://www.jacc.org/doi/full/10.1016/j.jcin.2023.02.003
IV. Troponins
- Age-Specific Cut-Offs Needed for Cardiac Troponin Tests? https://www.medscape.com/viewarticle/992167
- Myocardial Injury Thresholds for 4 High-Sensitivity Troponin Assays in U.S. Adults https://www.jacc.org/doi/full/10.1016/j.jacc.2023.03.403
- What Is a Normal Troponin Anyway? https://www.jacc.org/doi/10.1016/j.jacc.2023.03.404
- …
-
May 12 2023 This Week in Cardiology
12 mei 2023 · 25 min
Two new papers on left atrial appendage occlusion, the promise of DNA, statins in the elderly, and SGLT2 inhibitors are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
- When to Start a Statin Is a Preference-Sensitive Decision
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808
II. Left Atrial Appendage Closure
LAA Closure Outcomes Improve With CCTA: Swiss-Apero Subanalysis
https://www.medscape.com/viewarticle/991623
- Impact of Preprocedural Computed Tomography on Left Atrial Appendage Closure Success: A Swiss-Apero Trial Subanalysis https://doi.org/10.1016/j.jcin.2023.02.027
- Outcomes of percutaneous left atrial appendage occlusion device implantation in atrial fibrillation patients based on underlying stroke risk https://doi.org/10.1093/europace/euad049
III. Polygenic Risk Scores
- Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease https://jamanetwork.com/journals/jama/fullarticle/2761086
- Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program https://jamanetwork.com/journals/jamacardiology/article-abstract/2804439
- Validity of polygenic risk scores: are we measuring what we think we are? https://doi.org/10.1093/hmg/ddz205
IV. Statins in Older Patients
High Cholesterol in Seniors: Use Statins for Primary Prevention?
https://www.medscape.com/viewarticle/991801
V. SGLT2 Inhibitors
FDA Expands Use of Dapagliflozin to Broader Range of HF
https://www.medscape.com/viewarticle/991736
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abr…
-
May 5 2023 This Week in Cardiology
5 mei 2023 · 23 min
Beta-blockers post MI, public perception of statins, trust in the medical profession, BMI, and TAVI are the topics John Mandrola, MD, covers in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Post-MI Beta Blockers
Long-term Beta-Blockers Not Needed After MI with Preserved Systolic Function? https://www.medscape.com/viewarticle/991542
- Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes https://heart.bmj.com/content/early/2023/04/16/heartjnl-2022-322115
- Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure
https://www.nejm.org/doi/full/10.1056/nejmoa1608029
II. Statin Perceptions
Statin Misinformation on Social Media Flagged by AI
https://www.medscape.com/viewarticle/991585
- Artificial Intelligence–Enabled Analysis of Statin-Related Topics and Sentiments on Social Media
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803988
III. BMI
BMI Is a Flawed Measure of Obesity. What Are Alternatives?
https://www.medscape.com/viewarticle/991210
IV. TAVI Access
Better Access to Transcatheter Aortic Valve Replacement Associated With Improved Outcomes
https://www.medscape.com/viewarticle/991573
- Regional Differences in Outcomes for Patients Undergoing Transcatheter Aortic Valve Replacement in New York State and Ontario https://doi.org/10.1016/j.cjca.2023.01.025
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and u…
-
Apr 28 2023 This Week in Cardiology
28 april 2023 · 30 min
Two studies of cardiac device infections, observational studies, RCTs, and our ways of knowing in Medicine are the topics discussed by John Mandrola, MD in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Cardiac Device Infection
Mortality Climbs When CIED Infections Are 'Delayed' After Implant
https://www.medscape.com/viewarticle/990692
- Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality
https://jamanetwork.com/journals/jamacardiology/fullarticle/2803627
- Low Utilization of Lead Extraction Among Patients With Infective Endocarditis and Implanted Cardiac Electronic Devices https://www.jacc.org/doi/full/10.1016/j.jacc.2023.02.042
- Cardiac Implantable Electronic Devices and Infective Endocarditis: A Call to Arms...∗ https://www.jacc.org/doi/full/10.1016/j.jacc.2023.02.043
II. Can RCTs be Emulated with Real World Evidence?
- Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses https://jamanetwork.com/journals/jama/fullarticle/2804067
- Randomized Trials vs Real-world Evidence https://jamanetwork.com/journals/jama/fullarticle/2804092
- Reanalyses of Randomized Clinical Trial Data
https://jamanetwork.com/journals/jama/fullarticle/1902230
III. Multi-Morbidity Effects in Trials
Pivotal CV Trials May Not Apply to Complex Patients
https://www.medscape.com/viewarticle/989129
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection …
-
Apr 21 2023 This Week in Cardiology
21 april 2023 · 29 min
John Mandrola, MD discusses early vs delayed AF ablation, a report on a devastating complication of AF ablation, and a potential crosswind for a major therapeutic fashion in electrophysiology. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Early Vs Delayed Ablation
- Impact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences
https://doi.org/10.1093/eurheartj/ehad247
- Diagnosis-to-Ablation Time and Recurrence of Atrial Fibrillation Following Catheter Ablation
https://www.ahajournals.org/doi/full/10.1161/CIRCEP.119.008128
- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
https://www.nejm.org/doi/full/10.1056/nejmoa2029980
- Progression of Atrial Fibrillation after Cryoablation or Drug Therapy
https://www.nejm.org/doi/full/10.1056/NEJMoa2212540
II Atrial-Esophageal Fistula
CT and Surgery Best Diagnose and Manage Esophageal Fistula
https://www.medscape.com/viewarticle/990933
- A worldwide survey on incidence, management and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: The POTTER-AF study https://doi.org/10.1093/eurheartj/ehad250
- Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial https://doi.org/10.1093/europace/euaa209
- Temperature monitoring and temperature-driven irrigated radiofrequency energy titration do not prevent thermally induced esophageal lesions in pulmonary vein isolation: A randomized study controlled by esophagoscopy before and after catheter ablation https://doi.org/10.1016/j.hrthm.2021.02.003
III High-Power Short-Duration Ablation
Short, High-Power Ablation on Par With Standard AF Ablation
https://www.medscape.com/viewarticle/972087
- Power-Fast Trial
https://clinicaltrials.gov/ct2/show/NCT04153747
You may also like:
Medscape editor-in-c…
-
Apr 14 2023 This Week in Cardiology
14 april 2023 · 22 min
SCAI consensus document on LAAC, semaglutide/tirzepatide disruption, NSAIDs, and interventional echocardiography are the topics discussed by John Mandrola, MD, on this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. SCAI Consensus Document
New Update on Left Atrial Appendage Closure Recommendations
https://www.medscape.com/viewarticle/990507
- SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure
https://doi.org/10.1016/j.jscai.2022.100577
- Transcatheter Left Atrial Appendage Closure Comes of Age
https://doi.org/10.1016/j.jscai.2023.100592
- EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update https://doi.org/10.1093/europace/euz258
II. Semaglutide and Tirzepatide Disruption
Tirzepatide Powers 'Unprecedented' Weight Loss in Obesity Trial
https://www.medscape.com/viewarticle/975061
- Obesity Management in Primary Care
https://reference.medscape.com/recap/982874
- The $76 Billion Diet Industry Asks: What to Do About Ozempic?
https://www.wsj.com/amp/articles/ozempic-wegovy-mounjaro-weight-loss-industry-89419ecb
III. NSAIDs and HF
NSAID Use in Diabetes May Worsen Risk for First HF Hospitalization
https://www.medscape.com/viewarticle/990642
- Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.jacc.2023.02.027
IV. Interventional Echocardiography
New ASE Guideline on Interventional Echocardiography Training
https://www.medscape.com/viewarticle/990520
- Recommendations for Special Competency in Echocardiographic Guidance of Structural Heart Disease Interventions: From the American Society of Echocardiography
https://doi.org/10.1016/j.echo.2023.01.014
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the M…
-
Apr 07 2023 This Week in Cardiology
7 april 2023 · 27 min
Chat GPT, a relatively unknown therapy for HFpEF, and two fun studies on statins and secondary prevention are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Artificial Intelligence and CHAT GPT
Can ChatGPT Replace Diabetes Educators? Perhaps Not Yet
https://www.medscape.com/viewarticle/990381
- Potential and Pitfalls of ChatGPT and Natural-Language Artificial Intelligence Models for Diabetes Education
https://doi.org/10.2337/dc23-0197
II. Exercise and HFpEF
AHA, ACC Advocate Supervised Exercise Training in HFpEF
https://www.medscape.com/viewarticle/990351
- Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
https://doi.org/10.1016/j.jacc.2023.02.012
III. Statins and Muscles
Statins Don't Worsen Muscle Injury From Moderately Intense Exercise
https://www.medscape.com/viewarticle/990473
- Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users https://doi.org/10.1016/j.jacc.2023.01.043
IV. Statins in Secondary Prevention
Treat to LDL Target or High-Intensity Statin for All With Clinical CAD: LODESTAR
https://www.medscape.com/viewarticle/989884
- Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease
https://jamanetwork.com/journals/jama/article-abstract/2802214
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Hosted by Simp…
-
Mar 31 2023 This Week in Cardiology
31 maart 2023 · 27 min
Diets, coronary artery calcium, statins, basic CAD knowledge, and AF ablation are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Diet
Some Diets Better Than Others for Heart Protection https://www.medscape.com/viewarticle/990305
- Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis https://doi.org/10.1136/bmj-2022-072003
Plant-Based Diets Not Always Healthy; Quality Is Key https://www.medscape.com/viewarticle/990178
- Association of Healthful Plant-based Diet Adherence With Risk of Mortality and Major Chronic Diseases Among Adults in the UK https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802814
II. CAC and Statins
- Using the Coronary Artery Calcium Score to Guide Statin Therapy https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.113.000799
III. Subclinical Atherosclerosis
Subclinical CAD by CT Predicts MI Risk, With or Without Stenoses https://www.medscape.com/viewarticle/990254
- Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort
A Prospective Observational Cohort Study 0799 https://www.acpjournals.org/doi/10.7326/M22-3027
- A Prospective Natural-History Study of Coronary Atherosclerosis https://www.nejm.org/doi/10.1056/NEJMoa1002358?url_ver=Z39.88-2003
IV. AF ablation
- Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation RecurrenceThe AWARE Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2802860
- Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial FibrillationThe CAPLA …
-
Mar 24 2023 This Week in Cardiology
24 maart 2023 · 25 min
Exercise, sudden cardiac death in sports, new TAVI data, behavioral psychology, EHR doing good things, maybe, and coffee are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Fitness and Longevity
Even Small Changes in Fitness Tied to Lower Mortality Risk https://www.medscape.com/viewarticle/989906
- Changes in Cardiorespiratory Fitness and Survival in Patients With or Without Cardiovascular Disease https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.027
II. SCD in Sports
Sports-Related Sudden Cardiac Arrest 'Extremely' Rare in Women https://www.medscape.com/viewarticle/990025
- Incidence of Cardiac Arrest During Sports Among Women in the European Union https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.015
- Sex-Related Differences in Sports-Related Sudden Cardiac Death Should Be Reflected in Guideline Screening Recommendations∗ https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.014
- Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort https://doi.org/10.1093/eurheartj/ehz897
III. EVOLUT Three Year Data
Encouraging 3-Year Data for TAVR in Low-Risk Patients: EVOLUT
https://www.medscape.com/viewarticle/989144
- Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017
- Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
https://www.nejm.org/doi/full/10.1056/nejmoa1816885
- Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://www.jacc.org/doi/10.1016/j.jacc.2020.12.052
IV. Behavioral Psychology
NUDGE-FLU: Electronic 'Nudges' Boost Flu Shot Uptake in Seniors https://www.medscape.com/viewarticle/989108
- The Effect …
-
Mar 17 2023 This Week in Cardiology
17 maart 2023 · 30 min
ACC Recap No. 2: Pacing in HFpEF, Oral PCSK9 inhibitor, PAH, soft thinking on adherence, and so called metabolically healthy obese are discussed by John Mandrola, MD, in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Pacing in HFpEF
No Exercise Boost From Pacemaker in HFpEF With Impaired HR Response: RAPID-HF https://www.medscape.com/viewarticle/989681
- Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection FractionThe RAPID-HF Randomized Clinical Trial https://jamanetwork.com/journals/jama/article-abstract/2802147
- Accelerated Pacing a Possible Strategy for Preserved-EF Heart Failure? https://www.medscape.com/viewarticle/987815
- Could a Breakthrough in Heart Failure With Preserved Ejection Fraction Just Take a Change of Pace? - https://www.medscape.com/viewarticle/988088
- Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2801001
- Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction https://doi.org/10.1016/j.jacc.2021.08.073
II Oral PCSK9i
Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering https://www.medscape.com/viewarticle/989655
- Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018
III PAH
'Unheard of' PAH Improvement With Novel Drug: STELLAR https://www.medscape.com/viewarticle/989612
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2213558
IV Medical Adherence
Waiving Co-Pays for CV Meds as Adherence Incentive Doesn't Cut Clinical Risk: ACCESS Trial https…
-
Mar 10 2023 This Week in Cardiology
10 maart 2023 · 27 min
ACC Recap Part 1: Sports, bempedoic acid NASCARs, tricuspid regurgitation, and more on revascularization of stable CAD. are the topics discussed by John Mandrola, MD, in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Sports Cardiology
Even Vigorous Exercise Appears Safe for Patients With Hypertrophic Cardiomyopathy: LIVE-HCM https://www.medscape.com/viewarticle/989351
- Lifelong endurance exercise and its relation with coronary atherosclerosis https://doi.org/10.1093/eurheartj/ehad152
- Increased average longevity among the "Tour de France" cyclists https://pubmed.ncbi.nlm.nih.gov/21618162/
II. Clear Outcomes
Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients: CLEAR Outcomes
https://www.medscape.com/viewarticle/989100
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://www.nejm.org/doi/full/10.1056/NEJMoa2215024
- Bodgan Enache Tweet https://twitter.com/bogdienache/status/1632143539965509632?s=20
III. TRILUMINATE Trial
Transcatheter Tricuspid Valve Repair Effective, Safe for Regurgitation: TRILUMINATE https://www.medscape.com/viewarticle/989103
- Transcatheter Repair for Patients with Tricuspid Regurgitation https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
- New Treatment Could Help Fix the Heart's 'Forgotten Valve.' https://www.nytimes.com/2023/03/04/health/tricuspid-valve-clip-leakage.html
- Rasha Al-Lamee Tweet https://twitter.com/rallamee/status/1632295242685612033?s=20
IV. REVIVED-BCIS
Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2 https://www.medscape.com/viewarticle/989101
- Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
Features:
CLEAR Positives and Cautions With Bempedoic Acid for Statin Intolerance https://www.medscape.com/viewarticle/989098
The TRILUMINATE Transcatheter Tricuspid …
-
Mar 3 2023 This Week in Cardiology
3 maart 2023 · 24 min
Renal denervation, AF ablation, omecamtiv mecarbil, and an ACC Preview are the topics discussed by John Mandrola, MD, in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AF Ablation
- Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures https://www.jacc.org/doi/10.1016/j.jacc.2022.11.060
II. Renal Denervation
Consistent BP Cut With Renal Denervation: More on RADIANCE https://www.medscape.com/viewarticle/989006
- Endovascular Ultrasound Renal Denervation to Treat HypertensionThe RADIANCE II Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2801849
- Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials https://jamanetwork.com/journals/jamacardiology/fullarticle/2802098
- Is There a Role for Renal Denervation in the Treatment of Hypertension? https://jamanetwork.com/journals/jamacardiology/fullarticle/2802099
III. Omecamtiv Mecarbil
FDA Declines Approval for Omecamtiv Mecarbil in HFrEF https://www.medscape.com/viewarticle/988948
IV. ACC Preview
ACC Scientific Session Returns Live, Virtually to New Orleans https://www.medscape.com/viewarticle/988803
- 'Faith Healing' and 'Subtraction Anxiety' in Unblinded Trials of Procedures https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.118.004665
Features
Mandrola's 5 Things to Look for at ACC 23 https://www.medscape.com/viewarticle/988808
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.…
-
Feb 24 2023 This Week in Cardiology
24 februari 2023 · 26 min
Reporting on potential fraud in medicine, AF, stroke, a possible new cholesterol-lowering drug, and the tone of debate in medical science are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Potential Fraud in Medicine
Inside the Big Business of Clogged Arteries https://www.medscape.com/viewarticle/988448
II. AF Screening and Stroke
STROKE AF at 3 Years: High AF Rate After Atherosclerotic Stroke https://www.medscape.com/viewarticle/988076
Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke https://jamanetwork.com/journals/jamaneurology/fullarticle/2795865
III. Bempedoic Acid
New Studies Give Bempedoic Acid a Bump as Lipid-Lowering Agent https://www.medscape.com/viewarticle/911100
- Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance https://doi.org/10.1016/j.ahj.2020.10.060
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol https://www.nejm.org/doi/full/10.1056/NEJMoa1803917
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease https://jamanetwork.com/journals/jama/fullarticle/2754792
- N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects https://www.nejm.org/doi/full/10.1056/NEJMc2031173
- Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment https://www.jacc.org/doi/10.1016/j.jacc.2021.07.022
IV. The Technique of Critical Appraisal
Why Evidence-Based Medicine Enthusiasts Could Use a Lesson in Persuasion https://www.medscape.com/viewarticle/988227
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abr…
-
Feb 17 2023 This Week in Cardiology
17 februari 2023 · 26 min
Bradyarrhythmia during AF screening, thrombolysis in stroke, NP vs MD care, and the most biased paper this year — on LAAO — are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Screening with ILR
- Ade Adamson Tweet https://twitter.com/AdeAdamson/status/1625878856820482048?s=20
- The Rapid Rise in Cutaneous Melanoma Diagnoses
https://www.nejm.org/doi/full/10.1056/NEJMsb2019760
- Loop Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext
- Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362
II. Thrombolysis in Mild Stroke
Thrombolysis Not Necessary in Mild Nondisabling Stroke: ARAMIS
https://www.medscape.com/viewarticle/988381
- PRISMS Trial https://jamanetwork.com/journals/jama/fullarticle/2687354
- Risk of selection bias assessment in the NINDS rt-PA stroke study https://pubmed.ncbi.nlm.nih.gov/35705913/
- Tissue Plasminogen Activator for Acute Ischemic Stroke https://www.nejm.org/doi/full/10.1056/NEJM199512143332401
- Effects of alteplase for acute stroke; Hacke et al meta-analysis https://journals.sagepub.com/doi/10.1177/1747493017744464
- Methodological survey of missing outcome data in an alteplase for ischemic stroke meta-analysis
https://onlinelibrary.wiley.com/doi/full/10.1111/ane.13656
- ECASS; Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke https://www.nejm.org/doi/full/10.1056/nejmoa0804656
- Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances https://pubmed.ncbi.nlm.nih.gov/32430395/
III. NP vs MD Care
This Doc Still Supports NP/PA Led Care ... With Caveats https://www.medscape.com/viewarticle/967073
- The Productivity …
-
Feb 10 2023 This Week in Cardiology Podcast
10 februari 2023 · 22 min
Drug and non-drug therapies for HFpEF, the search for AF, and exercise as medicine are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. SGLT2 Inhibitors in HFpEF
Dapagliflozin Gets Expanded Heart Failure Indication in Europe https://www.medscape.com/viewarticle/988034
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
II. HFpEF and Heart Rate
Accelerated Pacing a Possible Strategy for Preserved-EF Heart Failure? https://www.medscape.com/viewarticle/987815
III. Stroke and AF
STROKE AF at 3 Years: High AF Rate After Atherosclerotic Stroke https://www.medscape.com/viewarticle/988076
Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease https://jamanetwork.com/journals/jama/fullarticle/2780490
Cryptogenic Stroke and Underlying Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa1313600
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT https://pubmed.ncbi.nlm.nih.gov/28329139/
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke https://www.nejm.org/doi/full/10.1056/NEJMoa2101897
IV. Exercise as Medicine
Trending Clinical Topic: Exercise Prescription https://reference.medscape.com/viewarticle/985373
Effect of Moderate and Vigorous Aerobic Exercise on Incident Diabetes in Adults With Obesityhttps://pubmed.ncbi.nlm.nih.gov/36716009/
Features
Could a Breakthrough in Heart Failure With Preserved Ejection Fraction Just Take a Change of Pace? https://www.medscape.com/viewarticle/988088
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine h…
-
Feb 3 2023 This Week in Cardiology
3 februari 2023 · 21 min
A possible major breakthrough in thinking about diastolic dysfunction and HFpEF, MRI scanning and cardiac devices, and AF and dementia are the topics John Mandrola, MD, covers in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. New Thinking in HFpEF
Accelerated Pacing a Possible Strategy for Preserved-EF Heart Failure? https://www.medscape.com/viewarticle/987815
- Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2801001
- Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction https://doi.org/10.1016/j.jacc.2021.08.073
- A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056412
- Lenient versus Strict Rate Control in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa1001337
II. MRI and ICD Function
Legacy ICDs Exposed to MRI Still Shock, Pace as Needed https://www.medscape.com/viewarticle/987729
- Implantable Defibrillator System Shock Function, Mortality, and Cause of Death After Magnetic Resonance Imaging https://doi.org/10.7326/M22-2653
- 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices https://pubmed.ncbi.nlm.nih.gov/28502708/
III. AF and Dementia
Atrial Fibrillation and Dementia: What Do We Know?
https://www.medscape.com/viewarticle/985900
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
…
-
Jan 27 2023 This Week in Cardiology
27 januari 2023 · 25 min
Exercise for AF, drugs have more than one effect, AI bots and the future of medicine, and the good and bad news about prognosis in HF are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AF and Exercise
Aerobic Exercise Can Reduce AF Frequency, Severity: ACTIVE-AF https://www.medscape.com/viewarticle/957322
An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial https://www.jacc.org/doi/full/10.1016/j.jacep.2022.12.002
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
II. GLP-1 Inhibitors and Retinopathy
Eye Check Important Before Starting Semaglutide for Diabetes https://www.medscape.com/viewarticle/987418
Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes? https://doi.org/10.1016/j.dsx.2022.102696
III. AI Bot Passes USMLEs
AI Bot ChatGPT Passes US Medical Licensing Exams Without Cramming – Unlike Students https://www.medscape.com/viewarticle/987549
Performance of ChatGPT on USMLE: Potential for AI-Assisted Medical 2 Education Using Large Language Models https://www.medrxiv.org/content/10.1101/2022.12.19.22283643v2.full.pdf
Tyler Cowen Comments -- GPT and my own career trajectory https://marginalrevolution.com/marginalrevolution/2023/01/gpt-and-my-own-career-trajectory.html
IV. HF Prognosis
Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study https://doi.org/10.1093/eurheartj/ehac797
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://ww…
-
Jan 20 2023 This Week in Cardiology
20 januari 2023 · 25 min
The loop diuretic duels, adverse events during hospital admissions, BP accuracy, and, again, left main revascularization strategies (again) are the topics John Mandrola discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. TRANSFORM HF
Clarity on Torsemide vs Furosemide in HF: TRANSFORM-HF Published https://www.medscape.com/viewarticle/987128
• Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure https://jamanetwork.com/journals/jama/fullarticle/2800428
• RANSFORM-HF—Can We Close the Loop on Diuretics in Heart Failure? https://jamanetwork.com/journals/jama/fullarticle/2800445
II. Adverse Events in the Hospital
Adverse Events Reported in One Quarter of Inpatient Admissions https://www.medscape.com/viewarticle/987091
• The Safety of Inpatient Health Care https://www.nejm.org/doi/full/10.1056/NEJMsa2206117
III. BP Accuracy
Experts Demand Validation of Automatic Blood Pressure Devices
https://www.medscape.com/viewarticle/987032
IV. Left Main Coronary Artery Disease
Real-World Examination of Revascularization Strategies for Left Main Coronary Disease in Ontario, Canada
https://doi.org/10.1016/j.jcin.2022.10.016
Management of Left Main Coronary Artery Disease in Nonemergent Settings: The Heart of Multidisciplinary Teamwork https://doi.org/10.1016/j.jcin.2022.11.024
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of persona…
-
Jan 13 2023 This Week in Cardiology
13 januari 2023 · 25 min
FOURIER authors' response, a possible practice-changing paper in electrophysiology, and the ATLAS and CAPLA trials are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. FOURIER Authors Respond
Recount of FOURIER Data Finds Higher Mortality With Evolocumab; Trialists Push Back https://www.medscape.com/viewarticle/986634
Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data https://bmjopen.bmj.com/content/12/12/e060172
Letter to the Editor RE: "Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data". BMJ Open https://bmjopen.bmj.com/content/12/12/e060172.responses#letter-to-the-editor-re-restoring-mortality-data-in-the-fourier-cardiovascular-outcomes-trial-of-evolocumab-in-patients-with-cardiovascular-disease-a-reanalysis-based-on-regulatory-data-bmj-open-2022123060172
Risk of selection bias assessment in the NINDS rt-PA stroke study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202115/
Methodological survey of missing outcome data in an alteplase for ischemic stroke meta-analysis https://doi.org/10.1111/ane.13656
II. A Potential Practice-Changing Paper in Cardiac Pacing
Novel 'Cure' May Avert Lead Extraction in CIED Pocket Infections https://www.medscape.com/viewarticle/986762
Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections https://doi.org/10.1016/j.jacc.2022.10.022
Treatment of Localized Implantable Cardiac Device Pocket Infections https://doi.org/10.1016/j.jacc.2022.11.018
III. ATLAS Trial
Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations https:/…
-
Jan 6 2023 This Week in Cardiology
6 januari 2023 · 24 min
Damar Hamlin, obesity and semaglutide, Open Data and PCSK9 inhibitors, and TAVI vs SAVR trials are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Damar Hamlin
Five Thoughts on the Damar Hamlin Collapse
https://www.medscape.com/viewarticle/986550
II. Semaglutide and Obesity in Adolescents
FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up
https://www.medscape.com/viewarticle/986403
• Once-Weekly Semaglutide in Adolescents with Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2208601
III. Open Data and PCSK9 inhibitors
Evolocumab Added to Statins Cuts CV Events in FOURIER Trial
https://www.medscape.com/viewarticle/877348
• Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
https://bmjopen.bmj.com/content/12/12/e060172
• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
https://www.nejm.org/doi/full/10.1056/nejmoa1615664
• PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction https://pubmed.ncbi.nlm.nih.gov/34252181/
• Bendary Tweet https://twitter.com/DrBendary/status/1609849852979986432?s=20&t=FDDhGIofS_HQ4jxf8aHwBA
IV. Open Data and TAVI vs SAVR Trials
Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799937
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please con…
-
Dec 23, 2022, This Week in Cardiology Podcast
23 december 2022 · 27 min
The top ten stories of the year plus a few honorary mentions. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic Lees meer
I Annual Wrap Ups on Medscape
- Mandrola's Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607
- 2022 in Review Through a Cardiology Lens https://www.medscape.com/viewarticle/984505
- Top Cardiology Trials of 2022 https://www.medscape.com/viewarticle/985647
II REVIVED BCIS2
- Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa2206606
- PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862
- PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853
III GUIDE HF
- Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2
- CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO https://www.medscape.com/viewarticle/970278
- GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure https://www.medscape.com/viewarticle/957390
IV DECAAF II
- Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation The DECAAF II Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2793452
- DECAAF II: AF, Fibrosis Ablation Technique Falls Short, but Signs of Hope https://www.medscape.com/viewarticle/957469
V DANCAVAS
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854
- Judicious CVD Screening May Work in Men: DANCAVAS https://www.medscape.com/viewarticle/980153
- DANCAVAS:…
-
Dec 16, 2022 This Week in Cardiology Podcast
16 december 2022 · 27 min
BP control over the long term, omecamtiv mecarbil, incentives and Goodhart's law, and open science are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic Lees meer
I. Long-Term BP Control
- Final SPRINT Data Confirm Lower BP Is Better https://www.medscape.com/viewarticle/951572
- Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://jamanetwork.com/journals/jamacardiology/fullarticle/2797064
- Let's Not SPRINT to Judgment About New Blood Pressure Goals https://www.acpjournals.org/doi/full/10.7326/M15-3123
- Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle? https://doi.org/10.1016/j.amjmed.2016.04.022
II. Omecamtiv Mecarbil
- FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure https://www.medscape.com/viewarticle/985593
- Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF https://www.medscape.com/viewarticle/978355
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2025797
- Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction https://jamanetwork.com/journals/jama/fullarticle/2794362
- Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial https://doi.org/10.1093/eurheartj/ehac293
III. Measuring Quality of Care
- MIPS Quality Scores Don't Reflect Quality of Care: Study https://www.medscape.com/viewarticle/985396
- Association Between Individual Primary Care Physician Merit-based Incentive Payment System Score and Measures of Process and Patient Outcomes https://jamanetwork.com/journals/jama/article-abstract/2799153
- Pay for Performance When Slogans Overtake Science in Health Policy https://jamanetwork.com/journals/jama/fullarticle/279…
-
Dec 9, 2022 This Week in Cardiology Podcast
9 december 2022 · 22 min
Nudges, statins, AI, less-is-more in the ICU, myocarditis, exercise as medicine, and December in the hospital are the topics John Mandrola, MD, covers in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Nudges and Statin Prescribing
EHR Alerts to Both Doc and Patient May Boost Statin Prescribing
https://www.medscape.com/viewarticle/984944
Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing
https://jamanetwork.com/journals/jamacardiology/article-abstract/2798971
Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia
https://jamanetwork.com/journals/jama/fullarticle/2719307
Lack of Efficacy of a Salience Nudge for Substituting Selection of Lower-Calorie for Higher-Calorie Milk in the Work Place https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488787/
II. AI and Chest X-Ray
Single Chest X-Ray Could Predict 10-Year CVD Risk
https://www.medscape.com/viewarticle/984910
III. BOX Trial
Shorter Fever Prevention Duration Effective After Cardiac Arrest
https://www.medscape.com/viewarticle/984852
Duration of Device-Based Fever Prevention after Cardiac Arrest
https://www.nejm.org/doi/10.1056/NEJMoa2212528
Oxygen Targets in Comatose Survivors of Cardiac Arrest
https://www.nejm.org/doi/full/10.1056/NEJMoa2208686
Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest
https://www.nejm.org/doi/full/10.1056/NEJMoa2208687
Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure
https://www.nejm.org/doi/full/10.1056/NEJMoa2032510
IV. Myocarditis
Mortality Higher in Myocarditis After Virus Than After COVID Vax
https://www.medscape.com/viewarticle/985045
Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination
https://link.springer.…
-
Dec 2, 2022 This Week in Cardiology Podcast
2 december 2022 · 24 min
SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. EMPA Kidney
- EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD https://www.medscape.com/viewarticle/984439
- EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease https://www.medscape.com/viewarticle/983521
- Empagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204233
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://www.nejm.org/doi/10.1056/NEJMoa1811744
- Dapagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials https://doi.org/10.1016/S0140-6736(22)02074-8
II. Publishing Choices
- Motorcycle Rallies Linked to Spike in Organ Transplants https://www.medscape.com/viewarticle/984623
- Organ Donation and Transplants During Major US Motorcycle Rallies https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2798550
III. Second and Third Order Effects
- Heart Disease Deaths Spiked During COVID After 10-Year Decline https://www.medscape.com/viewarticle/984605
IV. Decision Support
- Patient App Aids Decisions on Anticoagulants: ENHANCE-AF https://www.medscape.com/viewarticle/984253
- A Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision‐Making Pathway https://www.ahajournals.org/doi/10.1161/JAHA.122.028562
V. Percutaneous Left Atrial Appendage Closure
- Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com…
-
Nov 18, 2022, This Week in Cardiology
18 november 2022 · 28 min
AHA 2022, Part 2: IRONMAN, ECMO-CS, CTS-AMI, and PROGRESSIVE AF are the trials John Mandrola, MD, reviews in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Pushback on PROMINENT
Zimerman Thread: https://twitter.com/AndreZimerman/status/1593019800036708353
II. IRONMAN
IRONMAN Galvanizes Case for IV Iron Repletion in Heart Failure
https://www.medscape.com/viewarticle/984030
Is Iron Replacement in Heart Failure Worth the Trouble?
https://www.medscape.com/viewarticle/983622
- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial https://doi.org/10.1016/S0140-6736(22)02083-9
III. ECMO-CS
Avoid Routine Early ECMO in Severe Cardiogenic Shock: ECMO-CS
https://www.medscape.com/viewarticle/983618
- Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062949
- Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.118.004905
IV. CTS-AMI
Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMI
https://www.medscape.com/viewarticle/983619
V. PROGRESSIVE AF
First-Line AF Ablation Cuts Risk of Progression vs Drug Therapy
https://www.medscape.com/viewarticle/983882
Role of Ablation Type and Risk Factors in Paroxysmal AF: PROGRESSIVE-AF Interview https://www.medscape.com/viewarticle/983474
- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
https://www.nejm.org/doi/full/10.1056/nejmoa2029980
- Progression of Atrial Fibrillation after Cryoablation or Drug Therapy
https://www.nejm.org/doi/10.1056/NEJMoa2212540
- Natural History of Subclinical Atrial Fibrillation …
-
Nov 11, 2022 This Week in Cardiology Podcast
11 november 2022 · 23 min
AHA 2022 Part 1: ISCHEMIA-EXTEND, STRONG-HF, chlorthalidone vs HCTZ, experts vs practitioners; torsemide vs furosemide; and TG lowering are discussed by John Mandrola, MD, in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AHA Meta-comments
II. ISCHEMIA-Extended
- ISCHEMIA-EXTEND: Conservative Stable CAD Management Holds Up https://www.medscape.com/viewarticle/983657
- Survival After Invasive or Conservative Management of Stable Coronary Disease https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062714
III. STRONG-HF
- Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870
- STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698
- Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial https://doi.org/10.1016/S0140-6736(22)02076-1
IV. DCP
- Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP https://www.medscape.com/viewarticle/983608
- HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science https://www.medscape.com/viewarticle/983614
V. TRANSFORM HF
- No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF https://www.medscape.com/viewarticle/983611
VI. PROMINENT
- Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial https://www.medscape.com/viewarticle/983610
- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2210645
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, R…
-
Nov 4, 2022 This Week in Cardiology Podcast
4 november 2022 · 22 min
AF conversion in the ED, HRT, a shining example of evidence-based medicine and less-is-more, multimorbidity, and what's coming at AHA are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic Lees meer
I. AF Conversion
- IV Potassium and Magnesium an Acute Treatment for AF? https://www.medscape.com/viewarticle/983137
- Association of Intravenous Potassium and Magnesium Administration With Spontaneous Conversion of Atrial Fibrillation and Atrial Flutter in the Emergency Department https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797474
II. HRT
- USPSTF Doesn't Change Postmenopausal Hormone Recommendations https://www.medscape.com/viewarticle/983349
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women https://doi.org/10.7326/0003-4819-117-12-1016
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal WomenPrincipal Results From the Women's Health Initiative Randomized Controlled Trial https://jamanetwork.com/journals/jama/fullarticle/195120
- Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal PersonsUS Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2797867
- Menopausal Hormone Therapy for Prevention of Chronic Conditions https://jamanetwork.com/journals/jama/fullarticle/2797897
III. BP Targets After Stroke Intervention
- Intensive BP Lowering Harmful in Acute Ischemic Stroke: ENCHANTED2/MT https://www.medscape.com/viewarticle/983176
- Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial https://doi.org/10.1016/S0140-6736(22)01882-7
IV. Multimorbidity
- ACC Issues Guidance on Integrating ASCVD and Multimorbidity Care https://www.medscape.com/viewa…
-
Oct 28 2022 This Week in Cardiology
28 oktober 2022 · 22 min
ERASE AF follow-up, recreational drugs and AF, etripamil, misuse of science, and diabetes as a cardiovascular risk factor are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Follow-up on ERASE AF
II. Recreational Drugs
Four Commonly Abused Drugs Linked With Atrial Fibrillation
https://www.medscape.com/viewarticle/983052
III. Etripamil
RAPID: Positive Data for Etripamil Nasal Spray in Paroxysmal SVT
https://www.medscape.com/viewarticle/982787
- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-announces-positive-results-phase-3
IV. Misuse of Science
When Bad Actors Hijack Good Research
https://www.medscape.com/viewarticle/982936
- Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31050775/
V. Diabetes as a Risk Factor
Diabetes Becoming Less Potent Risk Factor for CVD Events
https://www.medscape.com/viewarticle/982801
- Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 https://jamanetwork.com/journals/jama/fullarticle/2797494
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our …
-
Oct 21, 2022 This Week in Cardiology Podcast
21 oktober 2022 · 27 min
The ERASE AF ablation trial, left bundle pacing, finerenone, and perceptions of cardiology are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic Lees meer
I. AF Ablation
- Low-Voltage Myocardium-Guided Ablation Trial of Persistent Atrial Fibrillation https://evidence.nejm.org/doi/10.1056/EVIDoa2200141
- Approaches to Catheter Ablation for Persistent Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa1408288
- Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2793452
- Circumferential Pulmonary Vein Isolation Plus Low-Voltage Area Modification in Persistent Atrial Fibrillation: The STABLE-SR-II Trial https://www.jacc.org/doi/full/10.1016/j.jacep.2022.03.012
- Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2772281
- Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation https://www.ahajournals.org/doi/full/10.1161/CIRCEP.120.009288
II. Left Bundle Branch Area Pacing
- FDA OKs Medtronic Lead for Left Bundle Branch Pacing https://www.medscape.com/viewarticle/982577
- Left bundle branch area pacing outcomes: the multicentre European MELOS study https://academic.oup.com/eurheartj/article/43/40/4161/6671019
- Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy https://www.jacc.org/doi/full/10.1016/j.jacc.2022.07.019
- Early sudden distal conductor fracture of a stylet-driven lead implanted for left bundle branch area pacing https://doi.org/10.1016/j.hrcr.2022.10.004
- Repositioning and extraction of stylet-driven pacing lead…
-
Oct 14, 2022 This Week in Cardiology Podcast
14 oktober 2022 · 21 min
Chest pain evaluation in the ED, peer review, the NordICC trial, and a surgeon lost too early are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic Lees meer
I. Chest Pain Consensus Pathway
- ACC Issues Guidance on ED Evaluation of Acute Chest Pain https://www.medscape.com/viewarticle/982302
- 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee https://www.jacc.org/doi/10.1016/j.jacc.2022.08.750
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001030#d20522356e1
II. Peer Review
- Big Name Researchers May Get Special Treatment, Limiting New Science https://www.medscape.com/viewarticle/982193
- Nobel and Novice: Author Prominence Affects Peer Review https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4190976
- Editorial peer review for improving the quality of reports of biomedical studies https://www.cochrane.org/MR000016/METHOD_editorial-peer-review-for-improving-the-quality-of-reports-of-biomedical-studies
III. NordICC
- Colonoscopy Lowers CRC Risk and Death, but Not by Much: NordICC https://www.medscape.com/viewarticle/982143
- Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death https://www.nejm.org/doi/full/10.1056/NEJMoa2208375
- The arrogance of preventive medicine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117852/
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
IV. Domenico Pagano
- Surgeon Domenico Pag…
-
Oct 7, 2022 This Week in Cardiology
7 oktober 2022 · 22 min
Post-PCI antiplatelet therapy, palliative care in patients with HF, Watchman information on hospital websites, and HCM in athletes are the topics John Mandrola, MD, covers in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Post-Stent Antiplatelet Therapy
SMART-CHOICE 3-Year Results Support Dropping Aspirin After PCI
https://www.medscape.com/viewarticle/981741
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention https://jamanetwork.com/journals/jamacardiology/fullarticle/2796902
The Smart(est) Choice for Dual Antiplatelet Therapy is a Patient-Directed One https://jamanetwork.com/journals/jamacardiology/fullarticle/2796904
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention https://jamanetwork.com/journals/jama/fullarticle/2736564
II. Palliative Care in HF
Home-Based Palliative Care Improves Heart Failure Outcomes https://www.medscape.com/viewarticle/981715
Regional collaborative home-based palliative care and health care outcomes among adults with heart failure https://doi.org/10.1503/cmaj.220784
III. Watchman Info on Hospital Websites
Concern Over US Hospital Patient Information on LAA Closure https://www.medscape.com/viewarticle/981961
Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web Pages https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2797102
IV. HCM and Exercise in Athletes
Athletes With Mild HCM Can Likely Continue Competitive Sports https://www.medscape.com/viewarticle/981782
Impact of Exercise on Outcomes and Phenotypic Expression in Athletes With Nonobstructive Hypertrophic Cardiomyopathy https://www.jacc.org/doi/full/10.1016/j.jacc.2022.08.715
A novel clinical risk prediction model for sudden cardiac death in hypertrophic…
-
Sep 30, 2022 This Week in Cardiology Podcast
30 september 2022 · 27 min
Pulmonary embolism, coffee, when DOACs don't work, lipoprotein (a), and the marginal benefits of current CV therapy are the topics John Mandrola, MD, discusses in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Pulmonary Embolism
- Positive Data on Thrombectomy Catheter That Avoids Thrombolytics in Acute PE https://www.medscape.com/viewarticle/981322
- Acute Outcomes for the Full US Cohort of the FLASH Mechanical Thrombectomy Registry in Pulmonary Embolism https://eurointervention.pcronline.com/article/acute-outcomes-for-the-full-us-cohort-of-the-flash-mechanical-thrombectomy-registry-in-pulmonary-embolism
- PEERLESS Study https://clinicaltrials.gov/ct2/show/NCT05111613
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (HI-PEITHO) https://clinicaltrials.gov/ct2/show/NCT04790370
- A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study https://doi.org/10.1016/j.jcin.2018.12.022
II. Coffee Again
- Coffee Linked to Reduced Cardiovascular Disease and Mortality https://www.medscape.com/viewarticle/981518
Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709
- The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality: long-term outcomes from the UK Biobank https://doi.org/10.1093/eurjpc/zwac189
III. DOAC and Mechanical Valves
- PROACT Xa Trial of Apixaban With On-X Heart Valve Stopped https://www.medscape.com/viewarticle/981644
- Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial https://investors.artivion.com/news-releases/news-release-details/artivion-follows-recommendation-stop-proact-xa-clinical-trial
- PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Sa…
-
Sep 23, 2022 This Week in Cardiology Podcast
23 september 2022 · 27 min
In this week's podcast, John Mandrola, MD, discusses the PROTECTED TAVR trial, renal denervation, left atrial appendage closure and deprescribing aspirin. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Cerebral Embolic Protection After TAVI
- Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR https://www.medscape.com/viewarticle/980978
- Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/10.1056/NEJMoa2204961
- Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement https://doi.org/10.1016/j.jacc.2016.10.023
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- Randomised Trial Of Intravenous Streptokinase, Oral Aspirin, Both, Or Neither Among 17 187 Cases Of Suspected Acute Myocardial Infarction: Isis-2 https://doi.org/10.1016/S0140-6736(88)92833-4
II Renal Denervation
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial https://doi.org/10.1016/S0140-6736(22)01787-1
- A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials https://doi.org/10.1016/j.tcm.2022.05.009
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- A Controlled Trial of Renal Denervation for Resistant Hypertension https://www.nejm.org/doi/10.1056/NEJMoa1402670
III Percutaneous Left Atrial Appendage Occlusion (L…
-
Sept 16, 2022 This Week in Cardiology Podcast
16 september 2022 · 24 min
The safety of very low LDL-C, the win-ratio analytic method, sacubitril/valsartan, SGLT2 inhibitors, and percutaneous left atrial appendage closure are discussed in this week's podcast. Lees meer
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I PCSK9I
Evolocumab Benefits Accrue With Longer Follow-up: FOURIER OLE https://www.medscape.com/viewarticle/979950
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease https://www.nejm.org/doi/full/10.1056/nejmoa1615664
- Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061620
II Analytic Methods and Re-Analysis of Old Trials
- PARADISE-MI Results Obscured As Post Hoc Analysis Finds Flaws https://www.medscape.com/viewarticle/980776
- Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction https://www.nejm.org/doi/10.1056/NEJMoa2104508
- Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057429
- The Year's Most Important Study Adds to Uncertainty in Science https://www.medscape.com/viewarticle/904286
III SGLT2i Post MI
- Early Signal of Benefit for Empagliflozin in Acute MI: EMMY https://www.medscape.com/viewarticle/980180
- Empagliflozin in acute myocardial infarction: the EMMY trial https://doi.org/10.1093/eurheartj/ehac494
IV Percutaneous Left Atrial Appendage Closure
- Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/10.1016/j.jacep.2022.06.012
- Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data https://www.ahajournals.org/doi/10.1161/JAHA.118.011577
- Baseline Comorbidities And Bleeding Events Of Patients Unde…
-
Sep 9, 2022 This Week in Cardiology Podcast
9 september 2022 · 25 min
A potential new anticoagulant, surveillance stress testing, a trial misinterpretation, an old diuretic, and AI in cardiology are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic Lees meer
I. Factor XI inhibitors
- Factor XIa Inhibitor After MI, Stroke Encouraging in Early Phase 2 Studies https://www.medscape.com/viewarticle/979942
- AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke https://www.medscape.com/viewarticle/979860
II. Surveillance Stress Testing
- No Benefit of Routine Stress Test POST-PCI in High-Risk Patients https://www.medscape.com/viewarticle/979866
- Routine Functional Testing or Standard Care in High-Risk Patients after PCI https://www.nejm.org/doi/full/10.1056/NEJMoa2208335
III. New Diuretic for Acute Heart Failure
- Vintage Drug Atop IV Loop Diuretics Boosts Decongestion in ADHF: ADVOR https://www.medscape.com/viewarticle/979851
- Acetazolamide in Acute Decompensated Heart Failure with Volume Overload https://www.nejm.org/doi/full/10.1056/NEJMoa2203094
IV. AI in Cardiology
- In Blinded Trial, Artificial Intelligence Beats Sonographers for Echo Accuracy https://www.medscape.com/viewarticle/979857
- Video-based AI for beat-to-beat assessment of cardiac function https://www.nature.com/articles/s41586-020-2145-8
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
-
Sep 2 2022 This Week in Cardiology Podcast
2 september 2022 · 25 min
A second ESC review covering REVIVED, the DANCAVAS CV screening trial, DELIVER on dapagliflozin in HF with mildly reduced EF, and the INVICTUS trial of rivaroxaban in rheumatic heart disease. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic Lees meer
I REVIVED BCIS
- PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853
- Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
- Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa1100356
II DANCAVAS
- DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
III DELIVER Trial
- Dapagliflozin's HFpEF Benefit Recasts Heart Failure Treatment: DELIVER https://www.medscape.com/viewarticle/979855
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials https://doi.org/10.1016/S0140-6736(22)01429-5
IV Rheumatic Heart Disease
- Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease https://www.medscape.com/viewarticle/979861
- Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2209051
- Rivaroxaban in Patients with Atrial Fibr…